Fresenius SE & Co. KGaA (FRA:FRE) and Sartorius Aktiengesellschaft (FRA:SRT3) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Valuation and Earnings
This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Fresenius SE & Co. KGaA | N/A | N/A | N/A | N/A | N/A |
Sartorius Aktiengesellschaft | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Fresenius SE & Co. KGaA | N/A | N/A | N/A |
Sartorius Aktiengesellschaft | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent recommendations and price targets for Fresenius SE & Co. KGaA and Sartorius Aktiengesellschaft, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Fresenius SE & Co. KGaA | 1 | 3 | 11 | 0 | 2.67 |
Sartorius Aktiengesellschaft | 1 | 6 | 2 | 0 | 2.11 |
Fresenius SE & Co. KGaA presently has a consensus target price of €46.07, suggesting a potential upside of 15.69%. Sartorius Aktiengesellschaft has a consensus target price of €321.89, suggesting a potential downside of 30.40%. Given Fresenius SE & Co. KGaA's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fresenius SE & Co. KGaA is more favorable than Sartorius Aktiengesellschaft.
Summary
Fresenius SE & Co. KGaA beats Sartorius Aktiengesellschaft on 3 of the 3 factors compared between the two stocks.